Peter MacCallum Cancer Centre, Australia
Quick facts
| Founded | 1949 |
|---|
Phase 2 pipeline
- 177Lu-FAP-2286 · Oncology
177Lu-FAP-2286 is a radiolabeled antibody that targets folate receptor alpha (FRα) for the treatment of cancer. - 68Ga-FAPi-46
- Azacitidine and eltrombopag · Oncology, Hematology
Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferase enzymes, leading to increased expression of tumor suppressor genes. Eltrombopag is a thrombopoietin receptor agonist that stimulates platelet production. - Capecitabine Pill · Oncology
Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth. - Epcoritamab, lenalidomide and rituximab
Phase 1 pipeline
- Anti-LeY- scFv-CD28-ζ vector,.
- Early antibiotic cessation alert
- LeY CAR T cells
- N-methyl-pyrrolidone
- SoC systemic therapy
- TetMYB Vaccine
- VTP195183
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: